The discovery of a gene for migraine holds great promise in the quest for new approaches—possibly even a pill—for preventing the disease, says a panel of experts presenting data at the annual scientific meeting of the American Headache Society. So far, there is no therapy that prevents an attack.
Guy A Rouleau MD, whose Canadian and British research team was first to sequence the gene for migraine last fall, says for the first time since the discovery of the triptans in the 1980s, investigators seeking to develop new migraine therapies are excited about the possibility of preventive drugs for migraine. Triptans act by constricting blood vessels in the brain which in turn inhibit pain receptors which can block migraine in some patients. They are not considered preventative therapies.
"We may be moving toward developing a pill that would block the brain's pain channel that reacts to stimulation and causes pain in migraine," says Dr Rouleau. Sequencing the gene not only allows us to understand the disease – it also opens understanding of the pain pathways that trigger migraine pain." Dr Rouleau is director of the CHU Sainte-Justine Research Center and Full Professor in the Department of Medicine of the Université de Montréal.
"For the first time in decades, I have seen great interest by the research community," he said, "including the private pharmaceutical industry in developing preventive migraine therapies."
Dr Rouleau is part of a panel on "Migraine and Genetics" devoted to discussing the implications of sequencing the gene for migraine. The session will be on Friday, June 3. More than 500 migraine specialists in clinical practice and research from around the world attend the annual session chaired by R Allan Purdy MD, of Dalhousie University in Halifax, Nova Scotia.
"The discovery of a gene for migraine with aura last fall was important because it confirms the longstanding observation that migraine 'runs' in some families," Dr Purdy said. "The presence of genetic factors in a common form of migraine holds promise for developing an effective treatment."
Source: News Release
MBooth & Associates
June 1, 2011